🟢 Rezolute is trading 5.9% up today following positive FDA feedback on its Phase III program

Rezolute is trading 5.9% up at $5.20 following productive FDA Type B meeting outcomes for its Phase III ersodetug program in congenital hyperinsulinism.

• The stock is building on a recent 12.1% gain, with a key FDA update for the program expected in the second half of 2026.
• Rezolute is currently outpacing the broader biotech sector and major indices, supported by a strong risk-on rally in U.S. equities.